NCCN Guidelines Update Includes HEPZATO KIT for Uveal Melanoma
Source: Oncology Nursing News, February 2025
Updates to the NCCN guidelines recommend HEPZATO KIT for use in hepatic-dominant uveal melanoma as a Category 2A treatment option.
The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology to recommend HEPZATO KIT (melphalan for Injection/Hepatic Delivery System [HDS]) as a Category 2A treatment option for patients with hepatic-dominant metastatic uveal melanoma.
The Guidelines had previously limited the use of HEPZATO KIT to the treatment of patients with liver-confined metastases.